Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia

Inclusion Criteria: * Age \>18 years * Diagnosis of relapsed or refractory AML for which all potentially curative or standard salvage therapy options have been exhausted; OR AML without prior treatment who are not eligible for induction chemotherapy as defined as age \> or equal to 80 or age \> 70 with poor risk cytogenetics (3 or more abnormalities, -5/del(5q), 3q abnormalities, or -7) or stable co-morbidities that would preclude induction chemotherapy such as LVEF less than 40% and/or DlCO less than 60% expected * ECOG 0-2 performance status * Biochemical values within the following range * Serum creatinine \<2x upper limit of normal * Total bilirubin \<1.5x upper limit of normal * AST and ALT \<2x upper limit of normal * Recovery from non-hematologic toxicity from prior chemotherapy * Able and willing to provide informed consent Exclusion Criteria: * Allergy to tetracycline or minocycline * Uncontrolled intercurrent illness such as uncontrolled diabetes or active uncontrolled infection * Active systemic bacterial, fungal, or viral infection * Concomitant use of linezolid or chloramphenicol that are known to inhibit mitochondrial protein synthesis * Pregnant or breast feeding * Known active CNS involvement with AML * Neurologic symptoms related to uncontrolled illnesses or unexplained causes * Psychiatric illness that would limit compliance with study * Receiving systemic chemotherapy other than hydroxyurea to control circulating blast counts. Concomitant hydroxyurea is permitted, but only in the first cycle of therapy * Prior therapy with tigecycline as an anti-cancer therapy or any use of the drug in the last month * Use of other investigational anti-leukemic therapy within 14 days of registration